FlowMetric Europe Headquarters Moves to Zambon OpenZone Campus
FlowMetric Europe, a wholly owned subsidiary of FlowMetric Life Sciences, is excited to announce that it will be opening its expanded European Headquarters office within the OpenZone campus (www.openzone.it), effective January 28th, 2019. The OpenZone scientific campus, a center of excellence for research and innovation located in Bresso, Italy is fully dedicated to the Life Sciences, has over 7,500 square meters of laboratory space, and hosts 22 companies focused on the biotechnology, pharmaceutical, and advanced gene therapy fields.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190108005310/en/
The new FlowMetric Europe Headquarters will be located within the Zambon OpenZone Campus at Via Antonio Meucci, 3, 20091 BRESSO (MI), a short distance from Milan center city. (Photo: Business Wire)
Mr. Renold Capocasale, founder and CEO of FlowMetric Life Sciences, is thrilled about the move and commented that "our global business has grown quickly and by relocating to a scientifically innovative and vibrant campus dedicated to the Life Sciences, while also increasing our office and lab space, will allow us to continue to grow our successful full-service flow cytometry CRO."
The new headquarters, containing three laboratories and offices, will be equipped with high dimensional flow cytometry instruments as well as a full tissue culture suite, in order to provide quality flow cytometry and cell sorting services to FlowMetric Europe’s European clients in the preclinical and clinical phases of development.
“We have a strong team here in Italy, true experts and industry leaders in the flow cytometry field,” notes Mr. Gianluca Carenzo, Vice President of FlowMetric Europe. “This move and expansion is necessary to support our continued client requests for additional global clinical trials in the EU.”
The FlowMetric Europe facilities will be located at Via Antonio Meucci, 3, 20091 BRESSO (MI), a short distance from Milan center city.
About FlowMetric Life Sciences
The FlowMetric Life Sciences family of companies is driven to provide Flow Cytometry Solutions in Precision Medicine. FlowMetric and FlowMetric Europe are a full service Flow Cytometry and Cell Sorting contract research organization. The company provides services for global partners in multiple therapeutic areas as well as throughout every phase of pharmaceutical development (preclinical research, non-GLP and GLP Toxicology studies as well as Clinical Phase 0-IV trials). Building on a combined 100 years of expertise in flow cytometry and advanced analysis platforms, FlowMetric Life Sciences adds value across the spectrum of drug discovery, translational research and clinical trials.
OpenZone is a campus dedicated to Life Sciences created by Zambon to perform research in an approach based on open innovation. Conceived with the mission of creating an entrepreneurial ecosystem to promote the exchange of knowledge and give rise to collaborations, the campus now accommodates over 20 companies, including some of the leading biotech, pharmaceutical and advanced gene therapy companies that are strongly oriented towards research and innovation, with internationally known and qualified experts. Thanks to an investment of 60 million Euros, OpenZone will double the existing space and number of laboratories by 2020, to a total area of 37,000 square meters that will provide space for up to 1,200 people.
FlowMetric Life Sciences
Rachel Bunting, MS, MBA
VP, Global Sales & Marketing
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease21.1.2019 12:00 | Tiedote
Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. ‘‘By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes.’’ The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with
Anticipation Builds as MWC19 Barcelona Approaches21.1.2019 12:00 | Tiedote
The GSMA today announced final updates for MWC19 Barcelona (formerly Mobile World Congress), including additional keynote speakers, participating companies, programmes and events. Taking place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet, MWC19 Barcelona is set to attract more than 107,000 professionals from over 200 countries and territories. “With the anticipated arrival of 5G, this year’s event is set to be one of the most exciting as the industry convenes to showcase Intelligent Connectivity across new technologies on the brink of reaching millions of people across the world,” said John Hoffman, CEO, GSMA Ltd. “Over the four days of MWC19, attendees will have the opportunity to hear from leaders who are driving innovation and we look forward once again to welcoming the mobile world to Barcelona.” Global Leaders to Keynote The GSMA announced the addition of several new keynote speakers for MWC19 including executives from lea
B2C2 Launches Streaming OTC Pricing with Point-and-Click Execution21.1.2019 12:00 | Tiedote
B2C2, one of the largest cryptocurrency liquidity providers and the leader in electronic OTC trading, today announced the launch of streaming pricing with point-and-click execution on its OTC platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005063/en/ Max Boonen, Founder and CEO of B2C2 (Photo: Business Wire) For the first time, B2C2’s clients will be able to view and execute trades on a real-time two-way market, via the firm’s secure web interface. The new functionality allows market participants to easily monitor live pricing in user-defined quantities and execute with the click of a button, as they would on traditional FX trading platforms. The launch rounds out a number of milestones for B2C2 in 2018, including surpassing 2017 peak volumes; rolling out a completely redesigned front-end; forming integration partnerships with the major liquidity hubs; and launching a research offering. Founded in 2015, B2C2 i
Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel21.1.2019 11:00 | Tiedote
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals. “Medison has a strong organization with a proven track record of commercializing orphan products successfully, together with an infrastructure uniquely suited to supporting patients suffering from rare diseases in Israel and providing access to our potentially transformational thera
Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe21.1.2019 11:00 | Tiedote
W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile allows physicians to perform TEVAR in patients with smaller vessels where access is challenging and aortic anatomy is tortuous, expanding the availability of Gore’s thoracic stent graft to a greater population of patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005042/en/ GORE(R) TAG(R) Conformable Thoracic Stent Graft with ACTIVE CONTROL System (Photo: Business Wire) The GORE® TAG® Conformable Thoracic Stent Graft was modified to reduce the delivery profile of the 31, 37, and 40 mm device diameters by 2 Fr for all lengths. The reduction in profile, through the use of a smaller diameter primary sleeve, is the only change to the device. The stent graft leverages the same predictable outcomes of the time-teste
HCL 2030 Ecosystem Platform to Explore Societal Implications of Emerging Technology at the World Economic Forum21.1.2019 10:26 | Tiedote
HCL Technologies (HCL), a leading global technology company and the World Economic Forum’s Strategic Partner, today announced its largest presence to date at the side-lines of World Economic Forum’s Annual Meeting in Davos scheduled from 21st January 2019 to 25th January 2019. The company will host a three-day event in a special Pavilion that will feature a technology showcase, thought-leadership programs, as well as a number of high-level networking and social events throughout the tenure of the conference. The overarching theme of the HCL and Fast Company programs will explore how humanity’s relationship with technology will evolve through the next decade of rapid innovation. HCL has partnered with Fast Company to develop a thought-leadership track that includes three panel discussion breakfasts. As part of the theme of Human-Machine Harmony, HCL is launching the HCL 2030 Platform, together with its ecosystem of partners and stakeholders, that will conduct in-depth explorations and d
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme